Patients with resectable non–small cell lung cancer (NSCLC) often receive treatment before they undergo surgery. For such patients who achieve a pathologic complete response (pCR), the chances of survival are improved. However, only a small percentage of patients achieve a pCR with neoadjuvant chemotherapy alone. Adding the immune checkpoint inhibitor nivolumab (Opdivo) to platinum-doublet chemotherapy […]